Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is of fair value on EV/EBITDA.
Target Price
The average target price of IOVA is 8.7 and suggests 296% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell